Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its earnings results on Monday. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.05, Briefing.com reports. The company had revenue of $7.51 million for the quarter, compared to analyst estimates of $8.08 million. Enanta Pharmaceuticals had a negative return on equity of 4.94% and a negative net margin of 28.68%. The firm’s quarterly revenue was down 46.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.06) earnings per share.

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 4.4678% during mid-day trading on Tuesday, reaching $40.2201. The company’s stock had a trading volume of 172,160 shares. Enanta Pharmaceuticals has a 1-year low of $21.00 and a 1-year high of $41.20. The company’s market capitalization is $767.52 million. The firm’s 50 day moving average price is $36.29 and its 200-day moving average price is $32.18.

A number of brokerages have issued reports on ENTA. Robert W. Baird boosted their target price on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday. Zacks Investment Research raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. JMP Securities raised Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price on the stock in a research report on Tuesday, July 11th. BidaskClub lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, ValuEngine raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $33.00.

ILLEGAL ACTIVITY WARNING: This story was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/08/enanta-pharmaceuticals-inc-enta-issues-earnings-results.html.

Several institutional investors have recently bought and sold shares of ENTA. First Manhattan Co. raised its position in Enanta Pharmaceuticals by 6.4% in the second quarter. First Manhattan Co. now owns 934,700 shares of the biotechnology company’s stock valued at $33,630,000 after buying an additional 56,200 shares during the last quarter. Vanguard Group Inc. raised its position in Enanta Pharmaceuticals by 7.2% in the first quarter. Vanguard Group Inc. now owns 792,165 shares of the biotechnology company’s stock valued at $24,399,000 after buying an additional 53,007 shares during the last quarter. State Street Corp raised its position in Enanta Pharmaceuticals by 31.8% in the first quarter. State Street Corp now owns 748,824 shares of the biotechnology company’s stock valued at $23,063,000 after buying an additional 180,586 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Enanta Pharmaceuticals by 129.7% in the first quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock valued at $12,723,000 after buying an additional 233,265 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. raised its position in Enanta Pharmaceuticals by 50.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 356,000 shares of the biotechnology company’s stock valued at $10,965,000 after buying an additional 120,000 shares during the last quarter. Institutional investors and hedge funds own 65.95% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.